anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: ALENDRONIC ACID
Trial phase: Not Applicable
ATC code: M05BA04 | M05BB03 | M05BB05 | M05BB06
SMILES: NCCCC(O)(P(=O)(O)O)P(=O)(O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: 70mg po every week for 12 months.

Alendronate Sodium: H20080172
Eligibility criteria:
Inclusion Criteria:

(1) They were pathologically diagnosed with DTC including papillary or follicular carcinoma. (2) They received a near total thyroidectomy and radioiodine treatment. (3) TSH suppression should be at least one year before the study. (4) Bone mineral density (BMD) in lumbar spine and/or hip was tested by Dual-energy X-ray absorptiometry (DXA) at baseline, 6 month (m) and/or 12m follow up. 5) The diagnosis of osteoporosis was T-score ≤-2.5 SD at the lumbar spine, or hip.

Exclusion Criteria:

patients having medications for osteoporosis before TSH suppression treatment;
secondary osteoporosis ;
severe liver or kidney disease;
myelosuppression;
digestive disease;
long term use of immunosuppressive agent, estrogen or estrogen receptor modulators. This study was approved by the Institutional Review Board of Hospital Research Ethics. All the patients were fully acquainted with their treatment and consented to participate in the clinical trial.
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Ketamine 0.3mg/kg IVPB in 50ml NS over 15 minutes Morphine 0.1mg/kg IVP PRN at designated intervals
Eligibility criteria:
Inclusion Criteria:

Patients 18 years old and older presenting with acute generalized pain
Describes pain to be greater than or equal to 3 on the Visual Analogue Scale (VAS)
Provides informed consent

Exclusion Criteria:

Patients who are admitted to the hospital
Severe hypertension(≥180/100)
Presence of or suspected for traumatic head injury with or without loss of consciousness
Presence of or suspected for myocardial ischemia
Presence of or suspected alcohol intoxication
Hemodynamic instability
History of schizophrenia
History of Sickle cell crisis / presenting with acute sickle cell crisis
History of or suspected recreational substance abuse
History of or suspected diagnosis of headache or migraine
History of or suspected diagnosis increase in intracranial/intraocular pressure
Known or suspected pregnancy
Allergy to ketamine or morphine
Administration of opioids in previous 4 hours
Patients with language barriers or in altered mental status who are unable to describe pain
Patients weighing over 166kg
Intervention: Terconazole
Trial phase: Phase 3
ATC code: G01AG02
SMILES: CC(C)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 149
Group description: One applicator full at bedtime

Terconazole
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
Capable of providing written informed consent or assent
Currently not menstruating and not anticipating menses during treatment
If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
Negative pregnancy test
Other criteria as identified in the protocol

Exclusion Criteria:

Other infectious causes of vulvovaginitis
Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
Nursing mother
Use of any investigational drug within 30 days of enrollment
History of hypersensitivity to any ingredient/component of the formulations
Other criteria as identified in the protocol
Intervention: Metronidazole
Trial phase: Phase 3
ATC code: A01AB17 | A02BD01 | A02BD02 | A02BD03 | A02BD08 | A02BD11 | A02BD13 | A02BD15 | D06BX01 | G01AF01 | G01AF20 | J01RA03 | J01RA04 | J01RA10 | J01RA14 | J01XD01 | P01AB01 | P01AB51 | P01AB52
SMILES: Cc1ncc([N+](=O)[O-])n1CCO
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 96
Group description: One applicator full at bedtime

Metronidazole
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
Capable of providing written informed consent or assent
Currently not menstruating and not anticipating menses during treatment
If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
Negative pregnancy test
Other criteria as identified in the protocol

Exclusion Criteria:

Other infectious causes of vulvovaginitis
Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
Nursing mother
Use of any investigational drug within 30 days of enrollment
History of hypersensitivity to any ingredient/component of the formulations
Other criteria as identified in the protocol
Intervention: Terconazole
Trial phase: Phase 3
ATC code: G01AG02
SMILES: CC(C)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 102
Group description: One applicator full at bedtime

Terconazole
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
Capable of providing written informed consent or assent
Currently not menstruating and not anticipating menses during treatment
If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
Negative pregnancy test
Other criteria as identified in the protocol

Exclusion Criteria:

Other infectious causes of vulvovaginitis
Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
Nursing mother
Use of any investigational drug within 30 days of enrollment
History of hypersensitivity to any ingredient/component of the formulations
Other criteria as identified in the protocol
Intervention: Midodrine
Trial phase: Phase 4
ATC code: C01CA17
SMILES: COc1ccc(OC)c(C(O)CNC(=O)CN)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
Eligibility criteria:
Inclusion Criteria:

age >=18 patients who complained of dizziness
Orthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=10

Exclusion Criteria:

Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month
Heart failure or Chronic renal failure
Patients who cannot or do not want to write questionaires.
Poor drug compliance
Intervention: Pyridostigmine Bromide
Trial phase: Phase 4
SMILES: CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
Eligibility criteria:
Inclusion Criteria:

age >=18 patients who complained of dizziness
Orthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=10

Exclusion Criteria:

Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month
Heart failure or Chronic renal failure
Patients who cannot or do not want to write questionaires.
Poor drug compliance
Intervention: Fluconazole
Trial phase: Phase 4
ATC code: D01AC15 | J01RA07 | J02AC01
SMILES: OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
Eligibility criteria:
Inclusion Criteria:

age >=18 patients who complained of dizziness
Orthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=10

Exclusion Criteria:

Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month
Heart failure or Chronic renal failure
Patients who cannot or do not want to write questionaires.
Poor drug compliance
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: The participants started sitagliptin at week 0
Eligibility criteria:
Inclusion Criteria:

Japanese T2DM patients, who are OAD naïve or receive 4-week wash out of one OAD (glinides, alpha-GI, metformin) before randomization.
HbA1c:6.0-8.0 %
BMI:18-30 kg/m2
Age:20-75 years old
CrCl: > 60mL/min

Exclusion Criteria:

Patients on DPP-4 inhibitors or glimepiride
Patients treated with pioglitazone
Patients with moderate/severe renal impairments
Patients with insulin or GLP-1 receptor agonists
Intervention: Glimepiride
Trial phase: Phase 4
ATC code: A10BB12 | A10BD04 | A10BD06
SMILES: CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: The participants started glimepiride at week 0
Eligibility criteria:
Inclusion Criteria:

Japanese T2DM patients, who are OAD naïve or receive 4-week wash out of one OAD (glinides, alpha-GI, metformin) before randomization.
HbA1c:6.0-8.0 %
BMI:18-30 kg/m2
Age:20-75 years old
CrCl: > 60mL/min

Exclusion Criteria:

Patients on DPP-4 inhibitors or glimepiride
Patients treated with pioglitazone
Patients with moderate/severe renal impairments
Patients with insulin or GLP-1 receptor agonists
Intervention: Tofacitinib
Trial phase: Not Applicable
ATC code: L04AA29
SMILES: C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Tofacitinib (5 mg tablet taken by mouth twice a day) for 3 months.
Eligibility criteria:
Inclusion Criteria:

Age >= 18 years old
Diagnosis of alopecia areata with >50% scalp involvement, alopecia totalis, or alopecia universalis
Hair loss present for at least 6 months
No treatment for alopecia areata in past 2 months
No evidence of hair regrowth
Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication
Fluent in spoken and written English

Exclusion Criteria:

Age <18 years old
Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study
Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
Patients known to be HIV or hepatitis B or C positive
Patients with positive tuberculin skin test or positive QuantiFERON TB test
Patients with leukopenia or anemia
Patients with renal or hepatic impairment
Patients with peptic ulcer disease
Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors
Women of childbearing potential who are unable or unwilling to use birth control while taking the medication
Women who are pregnant or nursing
Intervention: Ketorolac Tromethamine
Trial phase: Phase 4
SMILES: NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 44
Group description: One time intra-operative IV ketorolac thromethamine administration

Ketorolac Tromethamine
Eligibility criteria:
Inclusion Criteria:

carpal tunnel release surgery candidates,
distal radius fracture surgery candidates

Exclusion Criteria:

under 18 years of age,
pregnant women,
prisoners
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 44
Group description: One time intra-operative 50ml IV normal saline administration

Saline
Eligibility criteria:
Inclusion Criteria:

carpal tunnel release surgery candidates,
distal radius fracture surgery candidates

Exclusion Criteria:

under 18 years of age,
pregnant women,
prisoners
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 220
Group description: Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.

ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
Eligibility criteria:
Inclusion Criteria:

Female
Undergoing gynecological robotic and/or laparoscopic surgery
Overnight hospitalization expected

Exclusion Criteria:

Fibromyalgia
Chronic pelvic pain
Relevant drug allergy
Conversion to laparotomy
Pregnant
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 220
Group description: Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.

ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
Eligibility criteria:
Inclusion Criteria:

Female
Undergoing gynecological robotic and/or laparoscopic surgery
Overnight hospitalization expected

Exclusion Criteria:

Fibromyalgia
Chronic pelvic pain
Relevant drug allergy
Conversion to laparotomy
Pregnant
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 220
Group description: Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.

ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
Eligibility criteria:
Inclusion Criteria:

Female
Undergoing gynecological robotic and/or laparoscopic surgery
Overnight hospitalization expected

Exclusion Criteria:

Fibromyalgia
Chronic pelvic pain
Relevant drug allergy
Conversion to laparotomy
Pregnant
Intervention: Midazolam
Trial phase: Phase 4
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 15
Group description: Patients received 0.2 mg/kg of intranasal midazolam
Eligibility criteria:
Inclusion Criteria:

Children aged 18 months-7 years, scheduled for a minor otolaryngology (ENT) surgical procedure requiring mask anesthesia
American Society of Anesthesiologists (ASA) Class 1 or 2
Parent willing and able to provide written informed consent
Parent willing and able to complete the OBD VAS

Exclusion Criteria:

ASA Class 3 or greater
History of allergy to midazolam or xylocaine
Presence of acute respiratory infection at time of surgery
Parent unwilling or unable to provide informed consent
Parent unwilling or unable to complete the OBD VAS
Intervention: Teneligliptin
Trial phase: Phase 3
ATC code: A10BH08
SMILES: [H][C@@]1(N2CCN(c3cc(C)nn3-c3ccccc3)CC2)CN[C@]([H])(C(=O)N2CCSC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 151
Group description: Teneligliptin for 52 weeks
Eligibility criteria:
Inclusion Criteria:

In case of combination therapy with Sulfonylurea, patients who has been receiving a stable dose and regimen of sulfonylurea for diabetes over 12 weeks before administration of investigational drug
Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug

HbA1c criteria:

monotherapy: 6.9% - 10.5%
combination therapy with Sulfonylurea: 7.4 - 10.5%
Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.

Exclusion Criteria:

Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)
Patients who are accepting treatments of arrhythmias
Patients with serious diabetic complications
Patients who are the excessive alcohol addicts
Patients with severe hepatic disorder or severe renal disorder
Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception
Intervention: Citrulline
Trial phase: Phase 1
SMILES: NC(=O)NCCC[C@H](N)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Intravenous (IV) citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
Eligibility criteria:
Inclusion Criteria:

Sickle cell disease genotypes (HbSS, HbS/β° thalassemia, HbS/β+thalassemia, HbSC)

Exclusion Criteria:

Presence of any acute illness defined by fever >100.4° F within the past 48 hours
Presence of sickle cell pain crisis defined by the presence of pain requiring oral or parental opioid therapy.
Presence of acute chest syndrome or presence of any other complication related to sickle cell disease requiring hospitalization such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, and patients with diabetes etc.
Severe anemia (hemoglobin < 5g/dL)
History of red blood cell transfusion within the last 14 days
Systemic steroid therapy within the last 48 hours
Pregnant (as confirmed by a negative urine pregnancy test) or lactating female
Alanine/aspartate transferase >2x upper limit of normal laboratory range for age.
Elevated serum creatinine >1.5mg/dL
Patients with an inability to give consent will be excluded
Medications that are known to be contra-indicated with use of L-citrulline (concurrent use of hydroxyurea will be allowed).
History of diabetes due to risk of electrolyte imbalance
Intervention: OXYTOCIN
Trial phase: Not Applicable
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 230
Group description: Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.

Oxytocin: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
Eligibility criteria:
Inclusion Criteria:

All pregnant women diagnosed with PROM without evidence of labor requiring induction
Gestational Age > 34 weeks
Bishop score < 6
Category I Fetal heart rate tracing

Exclusion Criteria:

Contraindication to Induction of Labor
Multiple gestation
Fetal Anomalies
Previous C-Section
HIV Positive Patients
Intervention: Heme arginate
Trial phase: Phase 2
SMILES: C=CC1=C(C)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C=C)c(C)c4CCC(=O)O)C(CCC(=O)O)=C3C.NC(N)=NCCCC(N)C(=O)O.[Fe+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
Eligibility criteria:
Inclusion criteria:

Signed informed consent
Men and women aged between 40 and 85 years (inclusive)
Body mass index < 35 kg/m2
Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study

Exclusion criteria (any of the following):

Known hypersensitivity to the study drug or any excipients of the drug formulation
Treatment with another investigational drug within 3 weeks prior to screening
History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
Severe renal failure (glomerula filtration rate < 30 ml/min)
Moderately or severe impaired left ventricular function (ejection fraction < 40%)
Moderately or severe impaired right ventricular function
Systolic pulmonary pressure > 45 mmHg
Acute or recent (<7 days) myocardial infarction
Child bearing potential
Intervention: Heme arginate
Trial phase: Phase 2
SMILES: C=CC1=C(C)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C=C)c(C)c4CCC(=O)O)C(CCC(=O)O)=C3C.NC(N)=NCCCC(N)C(=O)O.[Fe+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
Eligibility criteria:
Inclusion criteria:

Signed informed consent
Men and women aged between 40 and 85 years (inclusive)
Body mass index < 35 kg/m2
Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study

Exclusion criteria (any of the following):

Known hypersensitivity to the study drug or any excipients of the drug formulation
Treatment with another investigational drug within 3 weeks prior to screening
History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
Severe renal failure (glomerula filtration rate < 30 ml/min)
Moderately or severe impaired left ventricular function (ejection fraction < 40%)
Moderately or severe impaired right ventricular function
Systolic pulmonary pressure > 45 mmHg
Acute or recent (<7 days) myocardial infarction
Child bearing potential